News | Cath Lab | April 17, 2017

Study Finds Significant Variability in Doctors' Angioplasty Death Rates

Judging doctors on mortality data may not give the full picture

Study Finds Significant Variability in Doctors Angioplasty Death Rates

April 17, 2017 — Some doctors have higher or lower than expected death rates from coronary angioplasty procedures, also known as percutaneous coronary intervention (PCI). However, doctors should not be judged solely on the rate of patients who die from the procedure, as the rate is highly variable over time, according to a recent study in JACC: Cardiovascular Interventions

PCI is a nonsurgical procedure that improves blood flow to the heart. It requires cardiac catheterization, which is the insertion of a catheter tube and injection of contrast dye into the coronary arteries. Doctors use PCI to open coronary arteries that are narrowed or blocked by the buildup of atherosclerotic plaque. PCI may be used to relieve symptoms of coronary heart disease or to reduce heart damage during or after a heart attack.

The new study analyzed data from the National Cardiovascular Data Registry CathPCI Registry to determine how many physicians had mortality rates outside the expected norm. The study included 3,760 doctors who performed 2,343,693 PCI procedures. The researchers adjusted for a number of factors, including how sick patients were.

The researchers found a small but significant number of doctors (6.5 percent) with mortality rates above what would be expected, as well as a small but significant number (4.1 percent) with mortality rates below what would be expected.

PCI mortality rates for individual doctors may be useful for both doctors and hospitals to assess and monitor their care and see where they need improvement, said Jacob Doll, M.D., a cardiologist at the University of Washington in Seattle and lead author of the study. “It could drive hospitals and doctors to further improve the safety of a procedure that’s already low-risk. However, I don’t see this measure as ready for widespread use as a publicly reported measure or to influence payment.”

A limitation with assessing mortality rates is that it is rare for patients to die from PCI — for every 100 procedures, only slightly more than 1 percent of patients die, and for elective PCI, death is very rare.

“Any given doctor may have only one or two deaths a year — some years just by chance you may have two or four, which seems like a lot, and the next year, you may have none. This may be further confounded by the low number of deaths that can be ascribed to the procedure, and makes it challenging to know whether these differences are actually due to the care received,” Doll said.

A number of factors affect a physician’s PCI mortality rate, Doll said. 

Because procedures performed on sicker patients often have higher mortality rates, Doll and colleagues took this into account, by using what is called a risk standardized mortality rate (RSMR).

“This helps us interpret the results to determine who really has a higher-than-expected morality rate, and who has a higher actual mortality rate because they take care of sicker patients,” he said.

In an editorial accompanying the study, Michael McDaniel, M.D., an assistant professor of medicine at Emory University School of Medicine in Atlanta, said that doctors concerned about their mortality rate being reported publicly may avoid treating the highest-risk patients.

 

Related NCDR CathPCI Registry articles:

• Radial Access, Same-Day Cardiac Procedure Could Save $300 Million Annually

• New Report Highlights National Trends in Heart Disease Treatments

• Better Prognosis for Some PCI Patients When Operators Perform More Procedures
 

 

For more information: www.interventions.onlinejacc.org

Related Content

TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
htisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...